As recently reported in bestmag, the JCESR has over 30 patents for licensing to existing and start-up companies that are technically and financially capable of turning early-stage technology into commercial products.
Dave Holt, senior associate and licensing specialist, comments on the recent Court of Appeal decision Neurim v Generics [2022] EWCA Civ 359 and its implications on licensing Unitary Patents.
The UK and EU have implemented new competition law exemptions but what impact will this have on your agreements?
The reason we recommended involving specialist legal counsel at an early stage of a deal in the first part of this series is because there is always a risk the proposed deal may not work for some reason or, at least, does not work exactly as the parties originally envisaged.
According to many, the anticipated arrival of Humira biosimilars in the US next year has pushed AbbVie's drug to the precipice of the pharma industry’s biggest-ever patent cliff.
Potter Clarkson has maintained its position as one of the top four patent specialists in Europe, according to the latest Europe’s Leading Patent Law Firms report from the Financial Times.